Home
Conditions
Lymphoma

Clinical trial condition

Lymphoma

Explore clinical trials studying Lymphoma. Study availability and eligibility vary by location and protocol.

3,646 public trials 848 recruiting studies

Refine in advanced search Browse all conditions

Lymphoma trial results

Recruiting

On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma

NCT06503211

Conditions: Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations: PersonGen.Anke Cellular Therapeutice Co., Ltd. Hefei, Anhui, China

View Trial Details

Recruiting

Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment

NCT06496308

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations: Ruijin Hospital Shanghai, China

View Trial Details

Recruiting

A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma

NCT06494371

Conditions: Anaplastic Large Cell Lymphoma, Hemic and Lymphatic Diseases, Hodgkin Disease, +11 more
Locations: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China

View Trial Details

Recruiting

Paper-Based and Smartphone-Based Memory Supports

NCT06444841

Conditions: Alzheimer Disease, Brain Diseases, Central Nervous System Diseases, +20 more
Locations: UT Health Austin Comprehensive Memory Center Austin, Texas, United States

Baylor Scott & White Healthcare Temple, Texas, United States

Baylor University Waco, Texas, United States

View Trial Details

Recruiting

CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma

NCT06482684

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations: University Hospital of Mainz Mainz, Germany

Klinikum der Universität München Munich, Germany

View Trial Details

Recruiting

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

NCT06454968

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Peking Union Medical College Hospital Beijing, Beijing Municipality, China

View Trial Details

Recruiting

Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies

NCT06462248

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations: Prince of Wales Hospital Hong Kong, China

View Trial Details

Recruiting

Clinical Study of OR for Second-line Treatment of Refractory MZL

NCT06134284

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: The Second Affiliated Hospital of Zhejiang University, Ningbo First Hospital Hangzhou, Zhejiang, China

86-574-87085596 Ningbo, Zhejiang, China

The First Affiliated Hospital of Ningbo University Ningbo, Zhejiang, China

View Trial Details

Recruiting

Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow Microenvironment

NCT06439173

Conditions: Cytopenia, Diffuse Large B Cell Lymphoma, Hematologic Diseases, +14 more
Locations: Complejo Asistencial Universitario de Salamanca Salamanca, Spain

View Trial Details

Recruiting

A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma

NCT06436677

Conditions: Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Hemic and Lymphatic Diseases, +12 more
Locations: Peking University First Hospital Beijing, Beijing Municipality, China

Beijing Cancer Hospital Beijing, Beijing Municipality, China

Peking University Third Hospital Beijing, Beijing Municipality, China

View Trial Details

Lymphoma

Lymphoma trial results

Related conditions